These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
    Author: Turcotte LM, Correll CK, Reed RC, Moertel CL.
    Journal: Pediatr Blood Cancer; 2014 Apr; 61(4):737-9. PubMed ID: 24019247.
    Abstract:
    Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.
    [Abstract] [Full Text] [Related] [New Search]